Marketing-authorisation holder · United States
Alnylam Pharms Inc
4 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
4 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
4 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AMVUTTRA25mg base/0.5ml (eq 25mg base/0.5ml) · Solution | Vutrisiran | United States | Marketed | 2022 |
| GIVLAARI189mg base/ml (eq 189mg base/ml) · Solution | Givosiran | United States | Marketed | 2019 |
| ONPATTRO10mg base/5ml (eq 2mg base/ml) · Solution | Patisiran | United States | Marketed | 2018 |
| OXLUMO94.5mg base/0.5ml (eq 94.5mg base/0.5ml) · Solution | Lumasiran | United States | Marketed | 2020 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 4 | 4 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.